Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :


By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :


Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Spectral Medical Reports Revenue Increase in Q2 2019 Update

Stockhouse Editorial
0 Comments| August 15, 2019

Medical Company Spectral Medical Inc. (TSX: EDT, OTC: EDTXF, Forum) released its Q2 2019 financial results on Thursday, highlighting revenues of $1,041,000, compared to $234,000 for the same period last year.

For more revenue highlights, click here.

Seeking US FDA approval for its unique product to treat septic shock, Spectral recently provided investors an update on both the start-up of the Tigris trial as well as developments in Dialco, a wholly-owned subsidiary of Spectral.

FULL DISCLOSURE: Spectral Medical Inc. is a client of Stockhouse Publishing.

Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Metals & Mining

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.